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M. H. A. Hermans,e and P. C. Wevera
Department of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, ’s-Hertogenbosch, the Netherlandsa; Centre for Infectious Disease Control, National
Institute for Public Health and the Environment, Bilthoven, the Netherlandsb; Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht,
Utrecht, the Netherlandsc; Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, the Netherlandsd; and Molecular
Diagnostics, Jeroen Bosch Hospital, ’s-Hertogenbosch, the Netherlandse
Little is known about the effect of timing of antibiotic treatment on development of IgG antibodies following acute Q fever. We
studied IgG antibody responses in symptomatic patients diagnosed either before or during development of the serologic re-
sponse to Coxiella burnetii. Between 15 and 31May 2009, 186 patients presented with acute Q fever, of which 181 were included
in this retrospective study: 91 early-diagnosed (ED) acute Q fever patients, defined as negative IgM phase II enzyme-linked im-
munosorbent assay (ELISA) and positive PCR, and 90 late-diagnosed (LD) acute Q fever patients, defined as positive/dubious
IgM phase II ELISA and positive immunofluorescence assay (IFA). Follow-up serology at 3, 6, and 12 months was performed us-
ing IFA (IgG phase I and II). High IgG antibody titers were defined as IgG phase II titers of>1:1,024 together with IgG phase I
titers of>1:256. At 12 months, 28.6% of ED patients and 19.5% of LD patients had high IgG antibody titers (P 0.17). No statis-
tically significant differences were found in frequencies of IgG phase I and IgG phase II antibody titers at all follow-up appoint-
ments for adequately and inadequately treated patients overall, as well as for ED and LD patients analyzed separately. Addition-
ally, no significant difference was found in frequencies of high antibody titers and between early (treatment started within 7 days
after seeking medical attention) and late timing of treatment. This study indicates that early diagnosis and antibiotic treatment
of acute Q fever do not prohibit development of the IgG antibody response.
Q fever is a zoonosis, caused by the intracellular bacteriumCoxiella burnetii (18). The presentation of the disease is ex-
tremely variable; most individuals (60%) remain asymptomatic
after infection (18, 19). In symptomatic acute Q fever patients, the
most common presentations range from a (self-limiting) flu-like
illness to pneumonia or hepatitis. ChronicQ fever, which presents
mainly as endocarditis or vascular infection, develops in approx-
imately 2% of infected patients (5, 10). Until 2007, roughly 5 to 20
cases of acute Q fever were notified in the Netherlands each year,
and the seroprevalence was low (2.4% in 2006 and 2007) (20).
However, between 2007 and 2010, large Q fever outbreaks oc-
curred in an area in the south of the Netherlands where Q fever
was previously not endemic, with over 4,000 notified symptom-
atic cases (25).
Laboratory diagnosis of Q fever is based mainly on serologic
testing for antibodies against phase I and phase II antigens (18).C.
burnetii has two antigenic states: during acute Q fever infection,
antibodies against phase II antigens predominate, whereas high
phase I antibody titers are more prevalent in cases of chronic Q
fever (4, 6, 19). The most commonly used serologic test is the
immunofluorescence assay (IFA). Seroconversion usually takes
place 10 to 15 days after the onset of acute disease (18), with the
appearance of IgM antibodies against phase II antigens (IgM
phase II), followed by IgG antibodies against phase II antigens
(IgGphase II), IgMantibodies against phase I antigens (IgMphase
I), and finally IgG antibodies against phase I antigens (IgGphase I)
(4). Since 2009, PCR for detection ofC. burnetiiDNA has become
an important tool in the diagnosis of acute Q fever in our labora-
tory (21). PCR enables diagnosis of acute Q fever early after onset
of disease (the first 3 weeks after onset of symptoms), often before
seroconversion has taken place (21). As the serological response
develops, PCR becomes negative in patients who do not develop
chronicQ fever (21). Current international recommendations ad-
vise routine follow-ups to detect patients who develop a chronicQ
fever infection, consisting of at least three consecutive serologic
tests in the first year after diagnosis of acute Q fever (13, 26). Most
infected individuals are asymptomatic, but in the case of symp-
tomatic individuals, symptoms of acuteQ fever can last from10 to
90 days and usually resolve spontaneously. Antibiotic treatment
with doxycycline or fluoroquinolones is warranted only in symp-
tomatic patients to shorten duration of fever and to hasten recov-
ery of pneumonia if present (24).
For infections caused by Borrelia spp., e.g., borreliosis, which is
also treated with doxycycline (3, 11), it has been reported that
early antibiotic treatment may prohibit development of the IgG
antibody response in patients with erythemamigrans (1, 7, 16, 17)
or neuroborreliosis (7). As Q fever and borreliosis can both de-
velop into a chronic disease which can be difficult to diagnose,
there may be more similarities between the two than previously
thought. Little is known about the development of IgG antibodies
following antibiotic treatment of acute Q fever. The purpose of
this study is to investigate the IgG antibody response in symptom-
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atic patients diagnosed and treated either before or during devel-
opment of the serologic response to C. burnetii.
MATERIALS AND METHODS
Patients. Those eligible for this retrospective study were all symptomatic
patients diagnosed with acute Q fever between 15 and 31May 2009 at the
Department ofMedicalMicrobiology and Infection Control of the Jeroen
Bosch Hospital, ’s-Hertogenbosch, the Netherlands. Patients excluded
were those who were younger than 18 years of age, who were pregnant,
who had submitted an earlier sample for Q fever testing, or who had
positive serology at diagnosis that was later found to be negative when
paired with a subsequent negative tested sample.
Diagnostic workups in these acute Q fever patients were performed
according to a diagnostic algorithm for acuteQ fever introduced on 1May
2009 (10). In short, serum samples were screened with an enzyme-linked
immunosorbent assay (ELISA) for IgM phase II (Institut Virion/Serion
GmbH,Würzburg, Germany). Depending on the outcome of ELISA IgM
phase II, date of onset of disease, and inpatient or outpatient setting, either
an in-house PCR for C. burnetii DNA (21) or IFA for IgM and IgG anti-
bodies against phase I and phase II antigens (Focus Diagnostics, Inc.,
Cypress, CA) was performed (for more details, see Jager et al. [10]). IgG
antibody responses during follow-ups were evaluated by comparing two
groups of patients, the early-diagnosed (ED) group (negative ELISA IgM
phase II and positive PCR at the time medical attention was sought) and
the late-diagnosed (LD) group (positive or dubious ELISA IgM phase II
confirmed by positive IFA [IgG phase II and/or IgM phase II titers of
1:32] at the time medical attention was sought).
Serological follow-up. In line with the internationally recommended
routine follow-up of acute Q fever, patients in both groups were asked to
provide a serum sample at 3, 6, and 12 months after diagnosis (13, 26).
Follow-up serology was performed using IFA for IgG phase II and phase I
antibodies. Samples were titrated up to 1:4,096 and, if still positive, were
categorized as 1:4,096. Samples of patients with an IgG phase I titer of
1:1,024 at month 12 were analyzed using PCR, to check whether C.
burnetii DNA was still present. High IgG antibody titers in follow-up
samples were arbitrarily defined as IgG phase II titers of 1:1,024 in
combinationwith IgGphase I titers of1:256. This IgGphase I titer is two
dilutions lower than the cutoff titer for chronic Q fever of1:1,024 set by
the Dutch Q Fever Consensus Group (27).
Data collection. Outcome of serologic tests, the date of the onset of
disease, and the datemedical attentionwas sought were collected from the
laboratory information system (LIS). If unavailable in the LIS, the date of
the onset of disease was obtained by contacting the general practitioners
(GP). The dates of the onset of disease extracted from the LIS were con-
sidered more pertinent than those obtained retrospectively from the GP,
as the former were written on the laboratory form at the moment the
patient visited the GP. In addition, data on treatment (type, dosage, start
date, and duration of antibiotic treatment prescribed)were obtained from
theGP. For patients diagnosed during hospitalization, data were obtained
from medical records. Included patients were assigned with a unique
code, and identifying information was deleted from the database. Ade-
quate treatment was defined as treatment with a C. burnetii-covering an-
tibiotic at the appropriate dosage for at least 10 days (e.g., doxycycline, 200
mg/day; moxifloxacin, 400 mg/day; ciprofloxacin, 1,000 mg/day; or cot-
rimoxazole, 1,920 mg/day). Other dosage schemes or antibiotics were
considered inadequate for treating symptomatic acute Q fever patients.
Early antibiotic treatment was defined as starting treatment before diag-
nosis or within 7 days after seeking medical attention.
Data analysis. Descriptive characteristics of the ED and LD groups
were investigated by calculating themean and standard deviation,median
and interquartile range (IQR), and relative frequencies. Depending on the
variable, Student’s t test (age), Mann-Whitney U tests (nonparametric
data; e.g., total number of days between onset of disease and seeking
medical attention for diagnosis, seeking medical attention for diagnosis
and sample at 12-month follow-up, seekingmedical attention for diagno-
sis and start of adequate antibiotic treatment; comparing the frequencies
of IgG antibody titers), and Chi-square tests (gender, frequencies of high
antibody titers, and adequate, inadequate, and early treatment) were per-
formed to assess significant differences. Patients without at least one fol-
low-up sample were included in the descriptive characteristics but were
excluded from further analysis. Data were analyzed usingMicrosoft Excel
(Microsoft Corp.) and IBM SPSS Statistics version 19.0.0 (SPSS Inc.).
Additionally, a separate analysis was performed excluding LD patients
without IgG phase I antibodies at 3, 6, and 12 months. This was done
because it cannot be ignored that patients in the LD group, for whom no
PCRwas performed at the timemedical attentionwas sought andwho did
not develop IgG phase I antibodies during follow-up, are in fact patients
with a resolved Q fever infection and persisting IgG phase II antibodies.
RESULTS
Between 15 and 31 May 2009, 92 ED patients and 94 LD patients
were diagnosed. One ED patient (18 years of age) and four LD
patients (18 years of age, n 1; pregnant, n 1; submitted an
earlier sample for Q fever testing, n 1; positive serology at diag-
nosis that was tested negative in a paired retest with a consecutive
negative tested sample, n 1) did not meet the inclusion criteria.
Therefore, 91 acute Q fever patients were included in the ED
group and 90 patients in the LD group. Characteristics of both
groups are presented in Table 1. The date of the onset of disease
was available for 92.3% (84/91) of patients in the EDgroup and for
85.6% (77/90) in the LD group. Both groups showed comparable
results, except for time between onset of disease to seekingmedical
attention (median number of days [interquartile range]: ED, 4.5
[3 to 5]; LD, 12 [7.5 to 23.5]; P 0.00), which is in line with the
definition of both groups. In 79.0% of the patients, the GP applied
for the laboratory test, while in 21.0%, a hospital physician re-
quested the test.
In the diagnostic sera of the LD group, IgM phase II ELISAwas
positive in 95.6% (86/90); the remaining four samples showed a
dubious result. However, these four samples showed positive re-
sults for IFA IgM phase II and IgG phase II. IFA IgM phase I and
phase II was performed for 70 LD samples: all samples showed
positive results for IgM phase II, and 65.7% (46/70), 1.4% (1/70),
and 32.9% (23/70) were IgM phase I positive, dubious, and nega-
tive, respectively. IgG phase II was positive for 98.9% (89/90) of
samples, and one showed a dubious result, while IgG phase I was
TABLE 1 Characteristics of acute Q fever patients in the early- and late-
diagnosed groups
Characteristic
Value
Early diagnoseda
(n 91)
Late diagnosedb
(n 90)
Age (mean SD) 48 15 51 16
No. (%) of males 57 (62.6) 56 (62.2)
Median no. of days (IQR) from onset
of disease to seeking medical
attention for diagnosisc
4.5 (3 to 5)d 12 (7.5 to 23.5)d
Median no. of days (IQR) between
seeking medical attention for
diagnosis and sample at 12-month
follow-up
364 (360 to 371) 364 (359 to 369)
a Early-diagnosed group: negative ELISA IgM phase II and positive PCR.
b Late-diagnosed group: positive or dubious ELISA IgM phase II confirmed by positive
IFA (IgG phase II and/or IgM phase II titers of1:32).
c Based on 84 patients in the early-diagnosed group and 77 in the late-diagnosed group.
d Statistical significant difference (P 0.00): in line with the definition of the groups.
Wielders et al.
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positive in 35.6% (32/90), dubious in 1.1% (1/90), and negative in
63.3% (57/90) of the LD patients. Six patients (three ED patients
and three in the LD group) did not provide any follow-up samples
and thus were excluded from further analysis.
In the ED group, 26.4% (23/87) had high IgG antibody titers
(IgG phase II titers of1:1,024 in combination with IgG phase I
titers of 1:256) at month 3, 24.4% (21/86) at month 6, and
28.6% (24/84) at month 12. In the LD group, 16.7% (14/84) had
high IgG antibody titers at month 3, 18.5% (15/81) at month 6,
and 19.5% (16/82) at month 12. Differences between both groups
were not statistically significant. There were 7 patients (5 ED and 2
LD patients) that had high titers at all three follow-up appoint-
ments. In total, 71 (40 ED and 31 LD) of the 181 patients (39.2%)
had a high titer in at least one of their follow-up appointments.
Figure 1 presents the distribution of IgG phase I and phase II titers
in both groups at 12-month follow-up. PCR was negative for all
12-month samples with an IgG phase I titer of 1:1,024, except
for the one patient in this study that developed chronic Q fever
(this will be discussed later).
Figure 2 shows the percentage of patients with IgG phase I and
phase II antibody titers at 12 months after initial diagnosis in the
ED and LD groups. Although higher frequencies of the lower an-
tibody titers were observed in the LD group, the differences be-
tween both groups were not statistically significant (IgG phase I:
P 0.07; IgG phase II: P 0.11). There was a statistically signif-
icant difference between the IgG phase II antibody titers of the
groups, with the LD group having lower titers than the ED group
at 3 months after initial infection (P  0.02). IgG phase I titers,
however, showed a borderline significant difference (P 0.05). At
6months, a borderline significant difference was observed for IgG
phase II titers (P  0.05), while IgG phase I titers showed no
statistically significant difference (P 0.08) (data not shown).
Data on antibiotic treatment for patients with at least one fol-
low-up sample (n  175) could be obtained for 165 patients: 85
ED and 80 LD patients (two GPs did not participate in the study,
n  3 LD patients; treatment unknown, n  4 patients [1 ED, 3
LD]; dosage or duration of antibiotic unknown, n 3 patients [2
ED, 1 LD]). Adequate treatment was prescribed in 83.0% (137/
165) of the patients, 14.5% (24/165) received inadequate treat-
ment, and four patients (2.4%) did not receive any treatment (Ta-
ble 2). The median number of days between seeking medical
attention for microbiological diagnosis and the start of any treat-
ment as well as adequate treatment was zero for both groups,
though the range between both groups differed (ED4 to 13,
FIG 1 Distribution of IgG phase I and phase II antibody titers as determined by immunofluorescence assay at 12-month follow-up in acute Q fever patients. (a)
Early-diagnosed group (negative ELISA IgM phase II and positive PCR), n  84 samples; (b) late-diagnosed group (positive or dubious ELISA IgM phase II
confirmedby positive IFA (IgGphase II and/or IgMphase II titers of1:32),n 82 samples. The dashed box indicates high antibody titers. *, Patientwith proven
chronic Q fever infection.
IgG Antibody Responses following Acute Q Fever
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LD  19 to 109 days; the minus sign means treatment started
before the diagnostic sample was submitted). A statistically signif-
icant difference was found for early (treatment started within 7
days after seeking medical attention) or late timing of treatment
between the ED and LD groups; ED patients received treatment
earlier, regardless of being treated adequately or not (P  0.04)
(Table 2). Among adequately treated patients only, we also found
a statistically significant difference for early treatment timing
(91.5% [ED] and 75.8% [LD] received treatment within 7 days
after seeking medical attention; P 0.01). No statistically signif-
icant differences were observed in frequencies of IgG phase I and
IgG phase II antibody titers at all follow-up appointments for
adequately and inadequately (including no treatment) treated pa-
tients overall, as well as for ED and LD patients analyzed sepa-
rately. One borderline significant result (P  0.06) was observed
for IgG phase I at the 12-month follow-up for patients treated
adequately, where LD patients showed lower antibody titers than
ED patients (median IgG phase I titer: ED, 1:64; LD, 1:32). Addi-
tionally, no significant difference was found in frequencies of high
antibody titers and in early or late timing of treatment (data not
shown).
Among those who provided a sample at all follow-up appoint-
ments, absence of IgG phase I antibody titers in all three follow-up
samples was observed in 2.4% (2/82) of the EDpatients and 13.0%
(10/77) of the LD patients (P 0.01). Treatment data were avail-
able for nine of these 12 patients; all nine received adequate treat-
ment. When the 10 LD patients without detectable IgG phase I
antibodies at any time point were excluded from analysis, 22.2%
(16/72) of the remaining cases in the LD group had high IgG
antibody titers at month 12 (P  0.37). IgG phase II antibodies
were present in all ED and LD patients.
One patientwith an aorta-femoral bypass (in the EDgroup and
treated adequately) showed a chronic Q fever serologic profile at
month 6 (IgG phase II titer of 1:4,096 and IgG phase I titer of
1:4,096). A positive serum PCR (threshold cycle [CT] value of
33.6) confirmed a chronic Q fever infection, and titers remained
high at month 12 (both IgG phase II and phase I titers of 1:
4,096) (Fig. 1a).
DISCUSSION
In this study, the development of IgG antibodies in early- and
late-diagnosed and treated groups of patients with symptomatic
acute Q fever infection were examined. The results show that IgG
phase I and phase II responses are not inhibited by early diagnosis
and subsequent treatment of the acute Q fever infection. No sig-
nificant differences in high antibody titers were observed between
the ED and LD groups at 3-, 6-, and 12-month follow-ups. Addi-
tionally, timing and adequateness of treatment did not result in
differences in the IgG phase I and phase II antibody responses.We
did find a statistically significant difference for earlier timing of
treatment in ED patients compared to in LD patients.
We observed statistically significant lower IgG phase II antibody
titers in theLDgroup than in theEDgroupat the 3-month follow-up
andborderline or nonsignificant differences in IgGphase I andphase
II titers at the other follow-ups. This observation contradicts the hy-
pothesis that, asobserved inborreliosis, earlydiagnosis and treatment
would prohibit the IgG antibody response.
Moreover, we found a statistically significant difference be-
tween both groups in the percentage of patients without a detect-
able IgG phase I antibody response: 2.4% in the ED group and
13.0% in the LD group. A possible explanation for this increased
proportion in the LD group is that these patients may in fact have
a resolved Q fever infection with persisting IgG phase II antibod-
ies. Transient reappearance or persistence of IgM antibodies in
such patients might result from nonspecific polyclonal activation
TABLE 2 Treatment of acute Q fever patients with at least one follow-
up sample in the early- and late-diagnosed groups
Characteristic
Value
Early diagnoseda
(n 85)
Late diagnosedb
(n 80)
No. (%) with adequate treatmentc 71 (83.5) 66 (82.5)
No. (%) with inadequate treatment 12 (14.1) 12 (15.0)
No. (%) with no treatment 2 (2.4) 2 (2.5)
No. (%) with early treatmentd 75 (88.2)f 61 (76.3)f
Median no. of days (IQR) from
seeking medical attention for
diagnosis to adequate treatmente
0 (0 to 1) 0 (3 to 7)
a Early-diagnosed group: negative ELISA IgM phase II and positive PCR.
b Late-diagnosed group: positive or dubious ELISA IgM phase II confirmed by positive
IFA (IgG phase II and/or IgM phase II).
c Defined by treatment with a Coxiella burnetii-covering antibiotic at the appropriate
dosage for at least 10 days (e.g., doxycycline, 200 mg/day; moxifloxacin, 400 mg/day;
ciprofloxacin, 1,000 mg/day; cotrimoxazole, 1,920 mg/day).
d Defined as starting treatment before diagnosis or within 7 days after seeking medical
attention, regardless of treatment being adequate or not.
e Based on n 70 patients in the early-diagnosed group and n 65 in the late-
diagnosed group; the start date of treatment was unknown for 1 early- and 1 late-
diagnosed patient.
f Statistical significant difference: P 0.04.
FIG 2 Percentage of acute Q fever patients with IgG phase I (a) and IgG phase
II (b) antibody titers as determined by immunofluorescence assay at 12-month
follow-up in the early-diagnosed and late-diagnosed group.
Wielders et al.
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due to another (undiagnosed) infection, as has been observed in at
least one case of legionellosis (unpublished). Omitting the LD
patients without detectable IgG phase I antibody response from
the analysis did not influence the outcome of our study, as the
percentage of remaining patients with high IgG antibody titers at
month 12 (22.2%) in the LD group remained lower than the per-
centage of ED patients (28.6%). Another possible explanation
might be that in these patients, IgG phase I antibodies were pro-
duced only for a short time and therefore were not detected at the
3-, 6-, and 12-month follow-ups. There were indeed two patients
in the ED group with PCR-proven acute Q fever in whom IgG
phase I antibodies were not detected during follow-ups.
The hypothesis that early antibiotic treatment could hamper
the development of the IgG antibody response was started by the
observation of this phenomenon in several studies of patients with
erythema migrans in the course of a Borrelia burgdorferi infection
(1, 7, 16, 17). As Q fever and borreliosis can both develop into a
chronic disease which can be difficult to diagnose and both are
treated with doxycycline, there may be more similarities. Ham-
mers-Berggren et al. found similar results for neuroborreliosis (7).
It was observed that antibodies against B. burgdorferi develop
gradually and slowly during the course of infection before treat-
ment (7–9, 12, 23). Early on in infection, patients show high IgM
and low IgG antibody levels, while those in the later stages have low
IgM and high IgG antibody levels. Seeing that patients that had early
treatment had low or no IgG antibody levels, it was suggested that
antibiotic treatment prevents the development of further IgG anti-
body response (7, 16), but it is less likely that the IgM response is also
inhibited (1). A similar observation that early antibiotic treatment
affected the antibody response to cytoplasmic proteins was also ob-
served inmice infected with Brucella melitensis (2).
As it was the third year of the 2007 to 2010 Dutch Q fever
epidemic, we expected that physicians in the high-risk area were
already aware of the symptoms of the acute infection. Lassche et al.
performed a questionnaire study among GPs in the high-risk area
with at least five acute Q fever patients in the first 6 months of
2009. In this study, 95% of the GPs (n  20) indicated that they
already started treatment when a Q fever infection was suspected
or when a patient had signs of pneumonia, without awaiting the
confirmation by microbiological tests (14). However, in our
study, we found a lower rate of GPs prescribing antibiotic treat-
ment before laboratory results were available (60.0% of patients
received treatment on the day of sampling or before, regardless of
treatment being adequate or inadequate). As we included samples
submitted to the laboratory between 15 and 31May 2009, without
selecting GPs with a minimum number of diagnosed patients, the
rate of starting treatment at the time of seeking medical attention
of 60.0% found in this study is probably a more accurate estimate
than the 95% from the questionnaire study.
Although our analysis did not show that early diagnosis and
treatment of acute Q fever diminish the development of the IgG
antibody response, it is of interest to evaluate if these findings can
be extrapolated to clinical outcome. The development of chronic
Q fever and Q fever fatigue syndrome after an acute Q fever infec-
tion are of particular interest. Up until 1 May 2012, no additional
chronic Q fever patients were diagnosed among the 181 patients
included, except the one adequately treated ED patient with a
known vascular risk factor who was diagnosed with chronic dis-
ease at the 6-month follow-up appointment. Another interesting
possibility for future research is to assess the effect of early antibi-
otic treatment on the time interval in which IFA IgG titers reach
maximum levels (in general, 4 to 8 weeks after the onset of disease
[15, 22]), but this would require more frequent acquisition of
follow-up samples.
In conclusion, our observations indicate that early diagnosis
and antibiotic treatment of acute Q fever do not prohibit devel-
opment of the IgG antibody response after follow-up appoint-
ments at 3, 6, and 12 months after initial diagnosis.
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